mononuclear cells, absent from human B cells, absent from human B cell myelogenic leukemia cells, absent from breast cancer cells, prostate cancer cells and cervical cancer cells; and the shed ovarian cancer cell antigen (i) is a single glycosylated polypeptide having a molecular weight of about 76 kDa to about 213 kDa as determined by SDS polyacrylamide gel electrophoresis (SDS-PAGE) under reducing conditions, and (ii) is absent from human peripheral blood mononuclear cells, absent from human B cells, absent from human B cell myelogenic leukemia cells, absent from breast cancer cells, prostate cancer cells and cervical cancer cells.

A2

REMARKS

In this Preliminary Amendment, claim 33 has been amended and new claims 40-64 have been added to more fully describe the invention. The claims as presented herein are fully supported by the instant specification, including the claims as originally filed. Consequently, no new matter has been introduced by the amended and new claims. The currently pending claims are 33 and 40-64. Amended claim 33 is presented separately on page 10, which is entitled "Version with markings to show changes made".

AUTHORIZATION

Should fee(s) additional to those paid herein be deemed necessary for the filing of this responsive amendment, the Commissioner is hereby authorized to charge any fee(s) which may be required to Deposit Account No. 13-4500, Order No. 3828-

4000US1.

Respectfully submitted,

MORGAN & FINNEGAN, L.L.P.

Date: November 28, 2001

By: Leslie Serunian
Leslie A. Serunian
Reg. No. 35,353

Correspondence Address:
MORGAN & FINNEGAN, L.L.P.
345 Park Avenue
New York, New York 10154-0053
(212) 758-4800 (Telephone)
(212) 751-6849 (Facsimile)

Version with markings to show changes made

33. (Amended) A method for detecting the presence and extent of ovarian cancer in a patient comprising:

(a) determining in a body fluid sample of said patient the level of [the antigen of claim 16] antibody-detectable antigen present on the surface of ovarian cancer cells, and shed from the ovarian cancer cells, said ovarian cancer cell surface antigen being:

(i) a single polypeptide having a molecular weight of about 76 kDa to about 213 kDa as determined by SDS polyacrylamide gel electrophoresis (SDS-PAGE) under reducing conditions;

(ii) absent from the group consisting of human peripheral blood mononuclear cells, human B cells, human B cell myelogenic leukemia cells, breast cancer cells, prostate cancer cells and cervical cancer cells; and

(iii) glycosylated; [in a sample of bodily fluid of said patient,] and

(b) correlating the quantity of said antigen with the [present] presence and extent of said ovarian cancer cells in said patient.